Lexaria Bioscience amends Japanese license deal; lowers minimum fees, drops exclusivity

Lexaria Bioscience Corp.

Original exclusive perpetual license with Premier becomes non-exclusive, ending Aug 31, 2025.
Quarterly minimum fees reduced: $84,000 for May & Aug 2024, then $174,000 through Aug 2025.
Previous schedule had fees up to $332,500/quarter from Nov 2025; now capped at $174,000.
Amendment effective March 15, 2024; signed by all parties on March 21, 2024.
Parentco assumed obligations after acquiring Premier in November 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.